Literature DB >> 6371037

Determining causation--a case study: adrenocorticosteroids and osteoporosis. Should the fear of inducing clinically important osteoporosis influence the decision to prescribe adrenocorticosteroids?

G H Guyatt, C E Webber, A A Mewa, D L Sackett.   

Abstract

It is generally accepted that exogenous adrenocorticosteroids cause clinically important osteoporosis. We have reviewed the evidence regarding causation in two stages: an examination of the strength of the methods used, and an application of five "diagnostic tests" for causation. The methods that have been used to investigate the association are weak: there have been no randomized clinical trials or prospective cohort studies. The measures of bone density used to quantify osteoporosis do not bear a close relation to clinically important outcomes. Nine analytic surveys and two before-after studies have examined the relation between steroids and osteoporosis. Although some have shown a strong relation, this finding has not been consistent. Evidence regarding temporality , dose-response gradient, and underlying mechanisms are conflicting. The available evidence does not substantiate a causal role of exogenous adrenocorticosteroids in producing clinically important osteoporosis, and does not support withholding steroid therapy on the basis of fears of osteoporosis induced pain and disability.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6371037     DOI: 10.1016/0021-9681(84)90100-0

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  8 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  J D Ringe
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

2.  Guidelines for reading literature reviews.

Authors:  A D Oxman; G H Guyatt
Journal:  CMAJ       Date:  1988-04-15       Impact factor: 8.262

Review 3.  Glucocorticoid use in rheumatoid arthritis.

Authors:  Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

4.  Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids.

Authors:  P N Sambrook; J A Eisman; M G Yeates; N A Pocock; S Eberl; G D Champion
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

Review 5.  Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.

Authors:  A Hodsman; J Adachi; W Olszynski
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

6.  Reduced strength of rat cortical bone after glucocorticoid treatment.

Authors:  G Ortoft; H Oxlund
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

7.  Long-term fracture risk following adult-onset asthma: a population-based study.

Authors:  L Joseph Melton; Ashok Patel; Sara J Achenbach; Ann L Oberg; John W Yunginger
Journal:  Osteoporos Int       Date:  2004-02-24       Impact factor: 4.507

8.  Applying evidence-based methods to the development and use of adverse outcome pathways

Authors:  Rob B M De Vries; Michelle Angrish; Patience Browne; Jan Brozek; Andrew A Rooney; Daniele S Wikoff; Paul Whaley; Stephen W Edwards; Rebecca L Morgan; Ingrid L Druwe; Sebastian Hoffmann; Thomas Hartung; Kristina Thayer; Marc T Avey; Brandiese E J Beverly; Maicon Falavigna; Catherine Gibbons; Katy Goyak; Andrew Kraft; Fernando Nampo; Amir Qaseem; Meg Sears; Jasvinder A Singh; Catherine Willett; Erin Y Yost; Holger Schünemann; Katya Tsaioun
Journal:  ALTEX       Date:  2021-04-08       Impact factor: 6.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.